Survival
PD
DISEASE
In this study, 10 (29%) patients in the decitabine‐RDHAP group and 4 (19%) patients in the RDHAP group achieved CR. The ORR was 40% in the decitabine‐RDHAP group and 33% in the RDHAP group with no significant difference in the response rate between the two groups (Response rates of decitabine‐RDHAP and RDHAP regimenAbbreviations: ORR, objective response rate; PD, progressive disease; RDHAP, rituximab, cisplatin, cytarabine, dexamethasone; SD, stable disease.At a median follow‐up of 12 months (hazard ratio [HR]: 4.109 (3.947–20.053)), the median PFS in the decitabine‐RDHAP and RDHAP groups was 7.0 months (95% confidence interval [CI]: 5.544–8.456) and 5.0 months (95% CI: 2.653–7.347) (Figure (A, B) OS and PFS for all patients. There were no significant differences between the decitabine‐RDHAP group and RDHAP group (